Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for CIPLA.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for CIPLA.BO and 80,000+ other tickers.
See exactly how CIPLA.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CIPLA.BO and 80,000+ other tickers.
Operating globally across India, the United States, South Africa, and other international markets, Cipla Limited, along with its affiliated entities, is engaged in the production, advancement, and distribution of pharmaceutical goods. Its operations are structured into two principal divisions: Pharmaceuticals and New Ventures. Beyond active pharmaceutical ingredients (APIs), the company delivers diverse formulations addressing a wide array of therapeutic areas. These encompass cardio-metabolic conditions (including treatments for MI, angina, heart failure, hypertension, arrhythmia, lipid…
No recent news available.